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Introduction
Aminoglycosides (Amgs) are highly potent, broad-
spectrum antibiotics with many desirable properties
for the treatment of human infections. Among resist-
ance mechanisms to Amgs inactivation by aminogly-
coside-modifying enzymes (AMEs) is the most
important both in terms of level and frequency of
resistance conferred to the bacterium [1]. There are
three family of AMEs including aminoglycoside
acetyltransferases (AACs), phosphotransferases
(APHs), and nucleotidyltransferases (ANTs). Each
group of enzymes consists of different isozymic
forms that differ in substrate regiospecificity for their
reactions [1]. Amgs modification has emerged in all
clinically relevant bacteria of both Gram-positive
(Staphylococcus spp., Enterococcus spp.) and Gram-
negative, including Proteus spp. strains [1-4]. These
enzymes are often plasmid-encoded but may also be
associated with transposable elements facilitating the
rapid dissemination of the genes in various bacterial
populations [1,5].
In this study we present occurrence of aac(6`)-Ib
gene encoding AAC(6`)-I enzyme in clinical strains of
Proteus mirabilis. 
Materials and methods
Bacterial strains. Proteus mirabilis strains were obtained from
patients admitted to University Hospital in Bialystok. The samples
were streaked onto MacConkey agar. Gram-negative bacteria were
identified using API 32E (bioMerieux, France), a standardized bio-
chemical identification system for Enterobacteriaceae. 
Susceptibility testing. The disk diffusion method was per-
formed to detection of Amgs resistance (patterns of resistance)
and other agents according to CLSI standards [6], using the fol-
lowing antibiotics: gentamicin, netilmicin, tobramycin,
amikacin, ampicillin, ampicillin-sulbactam, amoxicillin-clavu-
lanic acid, piperacillin-tazobactam, cefuroxime, ceftazidim,
cefotaxime, cefepime, aztreonam, tetracycline, ciprofloxacin,
imipenem, trimethoprim-sulfamethozaxole. The bacterial sus-
pensions (0.5 McFarland) had been inoculated on the surface of
Mueller-Hinton Agar, disks (Becton Dickinson) were added and
the suspensions were left to incubate in an incubator at 35°C.
Analysis was performed after 16-18 h of incubation by measur-
ing the zone diameters.
Minimal inhibitory concentrations (MICs) of gentamicin,
netilmicin, tobramycin and amikacin (range 0.016 to 256 μg/ml)
were determined by E-tests on Mueller-Hinton Agar according to
CLSI [6]. E. coli ATCC 25922 and E. coli ATCC 35218 were used
as standard strains.
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PCR experiments. Plasmid DNA was extracted and purified
from overnight cultures by using the Plasmid Mini kit (A&A
Biotechnology, Gdynia, Poland).The PCR method proposed by
Noppe-Leclercq et al. [7] was adopted in this study. Oligonu-
cleotide primers AMG-F1 (5`-TATGAGTGGCTAAATCGAT-3`)
and AMG-F2 (5`-CCCGCTTTCTCGTAGCA-3`) were
employed and early described by Ploy [8] and were used to
amplify a 395 bp fragment of gene encoding the AAC(6`)-I
enzyme. PCR amplification was carried out in a 25 µl volume
with the Cyclone 96 (PEQLAB Biotechnology, GmbH) thermal
cycler. The PCR mixtures contained: 25 pmol of each primers,
1x reaction buffer, 2 mM MgCl2, 1 µl of dNTPs, 0.5U of Delta2
DNA polymerase (DNA-Gdansk II, Gdansk, Poland), 2 µl of
template DNA and ultra pure H2O to final volume. The cycling
parameters of amplification were: initial denaturation at 94°C
for 2 min 20 s; denaturation at 94°C for 30 s, annealing at 54°C
for 40 s, and extension at 72°C for 80 s repeated for 45 cycles.
The final elongation step was at 72°C for 4 min. Products of
PCR were analyzed by electrophoresis at 5V/cm for 90 min in
1.8% agarose gel containing 0.5 µg/ml ethidium bromide in TBE
buffer and photographed on a UV transilluminator. The sizes of
the fragments produced in the amplifications were calculated
from their positions relative to the positions of the molecular
weight marker.
Results and discussion
Among examined strains of Proteus mirabilis (14) we
present seven isolates coded as Pm1 – Pm7 (Fig. 1).
The aac(6')-Ib gene was detected in five isolates (Pm1-
2, Pm5-7). The minimum inhibitory concentration
value of gentamicin, tobramycin, amikacin, and
netilmicin in three positive isolates (Pm1, Pm2, and
Pm6) were ≥256 µg/ml. The enzymes produced by
various bacteria can often be predicted from the antibi-
ogram data [4], but hidden genes could be present. One
Proteus mirabilis strain (Pm5) had non-acitve gene
aac(6')-Ib which MIC values of Amgs were located in
a criterion of the susceptibility. However, certain strain
(Pm4) did not have the aac(6')-Ib gene, but MICs of
aminoglycosides were ≥256 µg/ml. Pm3 strain (Fig. 1)
represents a group of isolates susceptible to four main
aminoglycosides. The AAC(6`)-I enzyme confers
resistance to tobramycin, amikacin, netylmicin, and
kanamycin. Only one component (gentamicin) can
remains active but in vivo use best avoided [1,4]. Of
all Amgs amikacin is the most resistant to the action of
AMEs. AAC(6')-I type enzymes can utilize amikacin
as substrate and confer resistance to this antibiotic in
addition to other Amgs [5]. Additionally, all positive
strains were resistant to tetracycline and ciprofloxacin.
Using a phenotypic approach the resistance pat-
tern according to activity of aac(6')-Ib gene can be
probably found in 6.4% of Proteus spp. strains [9].
Of all Enterobacteriaceae family the aac(6') genes
were the most frequently found genes and the isolat-
ed aac(6’)-Ib gene represented the most frequently
encountered resistance mechanism [10,11].
In general, aminoglycoside resistance rates
between different European countries were generally
higher in Italy, Portugal, Spain, Greece, France, the
UK, and Poland [12], but resistance of Proteus
mirabilis to aminoglycosides still remains low
[12,13].
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Fig. 1. Demonstration of aac(6`)Ib gene with PCR in agarose gel.
M1, molecular size marker M2 (pKO3/HinfI) (DNA-Gdansk II,
Gdansk, Poland); M2, molecular size marker M100-1000 bp
(DNA-Gdansk II, Gdansk, Poland), 395 bp band, aac(6`)Ib gene;
Lanes 1-7, numbers of clinical Proteus mirabilis strains Pm1-Pm7. 
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